Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. The Venowave is a medical compression pump that is lightweight, compact, battery operated, designed to treat and alleviate the symptoms associated with poor circulation.


TSXV:THRM - Post by User

Post by Smokey1958on Jun 15, 2021 8:43am
124 Views
Post# 33387175

Amazing Story!

Amazing Story!

July 7, 2020

"...entered into a binding letter of intent with Orpheus Medica Inc. ("Orpheus") to partner in the development of a rapid saliva test for the detection of the virus (SARS-CoV-2) causing COVID-19."

August 13, 2020

"...
it has completed its Phase 1 due diligence on Orpheus Medica's ("Orpheus") platform technology and plan for the development of a rapid saliva test..."

September 3, 2020


"Orpheus identified a series of polypeptides for the screening and detection of the virus (SARS-CoV-2) causing COVID-19."

October 21, 2020

"Therma & Orpheus are also pleased to announce the engagement of nanoComposix Inc...."

January 15, 2021

"...appointment of Ian Levine to the advisory board to assist with future scaling for the manufacture of CoviSafe™."

January 18, 2021

"Therma's CoviSafe™ prototype test showed an 86% sensitivity for samples with an RT_PCR Ct value below 30 and 100% sensitivity with Ct values of 25 or lower."

March 18, 2021

"...entered into an agreement with Safetest Diagnsticos("Safetest") of Brazil in partnership with the Federal University of Minas Gerais to conduct a clinical performance study of its AcuVidTMCOVID-19 Rapid Saliva-based Antigen Test."

March 24, 2021


"...entered into business agreement with Ridge Global, the consultancy founded by Governor Tom Ridge, the first U.S. Secretary of Homeland Security. The agreement focuses on supporting the Company's reach across the United States and Global marketplace business community along with extending policy advisory services in the U.S."

April 19, 2021


"...pleased to announce that it has received CE approval certification from an EU competent authority of Belgium for its AcuVid™ COVID-19 Rapid Antigen Saliva Test, and has secured a conditional purchase order for 100,000 units through a new global distribution partner, McWilliams Collective."

April 28, 2021

"The mutually beneficial partnership looks to bring Afero's innovation, security and tracking technology to Therma Bright's 15-minute COVID-19 rapid antigen screening solution."

May 21, 2021

"...announce that it has secured a development and manufacturing partnership with K-One MediTech to bring the Acuvid™ COVID-19 Rapid Antigen Saliva Test Kit to the marketplace."

May 27, 2021

"Company advances final validation efforts of its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test"

From concept to fruition in less than a year is extraordinary for a company like THRM. With virtually all the pieces in place and covid infections rising significantly in parts of South America, Asia and countries on the African continent AcuVid is poised to make a significant contribution in the fight against covid in these developing nations.

GLTE!!!



 



 

 

<< Previous
Bullboard Posts
Next >>